Krittamate Saisuwan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Krittamate Saisuwan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Sirinya Sitthirak
School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand
4 shared publications - Yanisa Rattanapan
Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand
4 shared publications - Aman Tedasen
Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand
2 shared publications - Hasaya Dokduang
Faculty of Medicine, Mahasarakham University, Maha Sarakham 44000, Thailand
2 shared publications - Rujira Nonsa-Ard
Faculty of Public Health, Mahasarakham University, Mahasarakham 44150, Thailand
2 shared publications - Saengrawee Thammawithan
Department of Systems Biosciences and Computational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
2 shared publications
Latest Publications
- Open Access
Identification and Characterization of Oxidative Stress-Related Prognostic Biomarkers in Acute Myeloid Leukemia Using Integrated Bioinformatics Analysis
Oxidative stress contributes to acute myeloid leukemia (AML) biology and treatment resistance, but its prognostic relevance remains incompletely defined. We analyzed 553 patients from GSE37642, treating paired GPL96/GPL97 measurements from 417 patients as the discovery cohort and GPL570 (n = 136) as a platform-defined internal–external validation cohort. Human genes annotated to cellular response to oxidative stress (GO:0034599) were retrieved from the Enrich GO Biological Process 2023 library; 110 genes were measurable in both cohort definitions. Discovery-only preprocessing was frozen before validation. Seventeen genes with nominal univariate Cox p < 0.05 entered cross-validated LASSO–Cox modeling, which retained a 13-gene signature (ATP13A2, AKT1, DAPK1, HSPA1A, LRRK2, CPEB2, CAMKK2, CCS, PRKAA1, RBM11, TP53, GPX1, and TPM1). Using the fixed discovery-derived coefficients and median cutoff (0.00807), the score separated high- and low-risk patients in discovery (log-rank p = 3.51 × 10−12; continuous-score HR = 3.24, 95% CI 2.46–4.29; C-index = 0.627, 95% CI 0.591–0.661) and remained associated with survival in platform-defined validation (log-rank p = 0.019; HR = 1.90, 95% CI 1.20–3.00; C-index = 0.580, 95% CI 0.519–0.641). Validation AUCs were 0.590, 0.621, and 0.655 at 1, 3, and 5 years. A fully nested five-fold diagnostic yielded a mean held-out C-index of 0.571. Adding the risk score to age improved the nested-model fit in validation (likelihood-ratio p = 0.028), but the improvement in discrimination was small (Delta C-index = 0.019) and its paired out-of-bag bootstrap 95% CI included zero (−0.070 to 0.056); corresponding Delta AUC intervals also included zero. Schoenfeld diagnostics did not indicate proportional-hazards violations. These findings support a biologically interpretable oxidative-stress-associated prognostic signal with modest cross-platform discrimination, while emphasizing the need for independent contemporary validation before clinical use.
Open AccessIdentification and Characterization of Oxidative Stress-Related Prognostic Biomarkers in Acute Myeloid Leukemia Using Integrated Bioinformatics Analysis
Oxidative stress contributes to acute myeloid leukemia (AML) biology and treatment resistance, but its prognostic relevance remains incompletely defined. We analyzed 553 patients from GSE37642, treating paired GPL96/GPL97 measurements from 417 patients as the discovery cohort and GPL570 (n = 136) as a platform-defined internal–external validation cohort. Human genes annotated to cellular response to oxidative stress (GO:0034599) were retrieved from the Enrich GO Biological Process 2023 library; 110 genes were measurable in both cohort definitions. Discovery-only preprocessing was frozen before validation. Seventeen genes with nominal univariate Cox p < 0.05 entered cross-validated LASSO–Cox modeling, which retained a 13-gene signature (ATP13A2, AKT1, DAPK1, HSPA1A, LRRK2, CPEB2, CAMKK2, CCS, PRKAA1, RBM11, TP53, GPX1, and TPM1). Using the fixed discovery-derived coefficients and median cutoff (0.00807), the score separated high- and low-risk patients in discovery (log-rank p = 3.51 × 10−12; continuous-score HR = 3.24, 95% CI 2.46–4.29; C-index = 0.627, 95% CI 0.591–0.661) and remained associated with survival in platform-defined validation (log-rank p = 0.019; HR = 1.90, 95% CI 1.20–3.00; C-index = 0.580, 95% CI 0.519–0.641). Validation AUCs were 0.590, 0.621, and 0.655 at 1, 3, and 5 years. A fully nested five-fold diagnostic yielded a mean held-out C-index of 0.571. Adding the risk score to age improved the nested-model fit in validation (likelihood-ratio p = 0.028), but the improvement in discrimination was small (Delta C-index = 0.019) and its paired out-of-bag bootstrap 95% CI included zero (−0.070 to 0.056); corresponding Delta AUC intervals also included zero. Schoenfeld diagnostics did not indicate proportional-hazards violations. These findings support a biologically interpretable oxidative-stress-associated prognostic signal with modest cross-platform discrimination, while emphasizing the need for independent contemporary validation before clinical use.
- Open Access
- 17 March 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (1) , 140
Lipemic Plasma Identified Blood Donors: Triglyceride Variability and Exploratory Machine Learning Analysis
Background/Objectives: Early detection of cardiometabolic irregularities is crucial for averting cardiovascular illness; however, demographic cohorts that consistently engage with healthcare systems like habitual blood donors are inadequately leveraged for metabolic monitoring. Methods: This study performed lipid profiling and cardiovascular risk assessment among blood donors identified with visually lipemic plasma during routine screening, in order to explore metabolic variability within this selected donor subgroup. Of 13,818 screened donors, 160 with lipemic plasma were included, and multivariable and machine-learning analyses were restricted to 90 donors with complete clinical data. Results: We observed substantial variability in triglyceride levels, with males displaying higher and more dispersed values. Correlation analysis indicated that triglycerides were associated with BMI and composite cardiovascular risk metrics, while age was the strongest contributor to the calculated 10-year cardiovascular risk score. Using a Random Forest classifier, elevated triglyceride levels were predicted with an AUC of 0.86; however, given the limited sample size, this analysis should be interpreted as exploratory and proof-of-concept in nature. Conclusions: In this selected subgroup of donors with lipemic plasma, clinically relevant hypertriglyceridemia was frequently observed. These findings suggest that routine donor data may provide opportunities for targeted metabolic monitoring, although the results cannot be generalized to the broader blood donor population. Further studies in larger and more representative cohorts are warranted.
- 17 March 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (1) , 140
Open AccessLipemic Plasma Identified Blood Donors: Triglyceride Variability and Exploratory Machine Learning Analysis
Background/Objectives: Early detection of cardiometabolic irregularities is crucial for averting cardiovascular illness; however, demographic cohorts that consistently engage with healthcare systems like habitual blood donors are inadequately leveraged for metabolic monitoring. Methods: This study performed lipid profiling and cardiovascular risk assessment among blood donors identified with visually lipemic plasma during routine screening, in order to explore metabolic variability within this selected donor subgroup. Of 13,818 screened donors, 160 with lipemic plasma were included, and multivariable and machine-learning analyses were restricted to 90 donors with complete clinical data. Results: We observed substantial variability in triglyceride levels, with males displaying higher and more dispersed values. Correlation analysis indicated that triglycerides were associated with BMI and composite cardiovascular risk metrics, while age was the strongest contributor to the calculated 10-year cardiovascular risk score. Using a Random Forest classifier, elevated triglyceride levels were predicted with an AUC of 0.86; however, given the limited sample size, this analysis should be interpreted as exploratory and proof-of-concept in nature. Conclusions: In this selected subgroup of donors with lipemic plasma, clinically relevant hypertriglyceridemia was frequently observed. These findings suggest that routine donor data may provide opportunities for targeted metabolic monitoring, although the results cannot be generalized to the broader blood donor population. Further studies in larger and more representative cohorts are warranted.
- Open Access
- 23 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 174
Network Pharmacology and Molecular Docking Identify Medicarpin as a Potent CASP3 and ESR1 Binder Driving Apoptotic and Hormone-Dependent Anticancer Activity
Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies due to late diagnosis, rapid progression, and frequent chemoresistance. Despite advances in targeted therapy, durable responses are uncommon, underscoring the need for novel multitarget agents capable of modulating key oncogenic networks. Medicarpin, a natural pterocarpan phytoalexin, exhibits diverse pharmacological activities; however, its molecular mechanisms in OC are poorly defined. This study employed an integrative in silico framework combining network pharmacology, pathway enrichment, molecular docking, and survival analysis to elucidate medicarpin’s therapeutic landscape in OC. A total of 107 overlapping targets were identified, resulting in a dense protein–protein interaction network enriched in kinase-mediated and apoptotic signaling pathways. Ten hub genes were emphasized: CASP3, ESR1, mTOR, PIK3CA, CCND1, GSK3B, CDK4, PARP1, CHEK1, and ABL1. Gene Ontology and KEGG analyses demonstrated substantial enrichment in the PI3K–Akt/mTOR and prolactin signaling pathways. Docking revealed the stable binding of medicarpin to CASP3 (−6.13 kcal/mol) and ESR1 (−7.68 kcal/mol), supporting its dual regulation of hormonal and apoptotic processes. Although CASP3 and ESR1 expression alone lacked prognostic significance, their network interplay suggests synergistic relevance. Medicarpin exhibits multitarget anticancer potential in OC by modulating kinase-driven and hormone-dependent pathways, warranting further experimental validation.
- 23 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 174
Open AccessNetwork Pharmacology and Molecular Docking Identify Medicarpin as a Potent CASP3 and ESR1 Binder Driving Apoptotic and Hormone-Dependent Anticancer Activity
Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies due to late diagnosis, rapid progression, and frequent chemoresistance. Despite advances in targeted therapy, durable responses are uncommon, underscoring the need for novel multitarget agents capable of modulating key oncogenic networks. Medicarpin, a natural pterocarpan phytoalexin, exhibits diverse pharmacological activities; however, its molecular mechanisms in OC are poorly defined. This study employed an integrative in silico framework combining network pharmacology, pathway enrichment, molecular docking, and survival analysis to elucidate medicarpin’s therapeutic landscape in OC. A total of 107 overlapping targets were identified, resulting in a dense protein–protein interaction network enriched in kinase-mediated and apoptotic signaling pathways. Ten hub genes were emphasized: CASP3, ESR1, mTOR, PIK3CA, CCND1, GSK3B, CDK4, PARP1, CHEK1, and ABL1. Gene Ontology and KEGG analyses demonstrated substantial enrichment in the PI3K–Akt/mTOR and prolactin signaling pathways. Docking revealed the stable binding of medicarpin to CASP3 (−6.13 kcal/mol) and ESR1 (−7.68 kcal/mol), supporting its dual regulation of hormonal and apoptotic processes. Although CASP3 and ESR1 expression alone lacked prognostic significance, their network interplay suggests synergistic relevance. Medicarpin exhibits multitarget anticancer potential in OC by modulating kinase-driven and hormone-dependent pathways, warranting further experimental validation.
- Open Access
Computational Investigation Identifies mTOR as a Primary Binding Target of Medicarpin in Cholangiocarcinoma: Insights from Network Pharmacology and Molecular Docking
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of biliary tract with poor prognosis and limited therapeutic alternatives. While targeted medicines only benefit a small subset of patients with specific genetic modifications, conventional chemotherapy offers negligible survival advantages. There is an urgent need for novel medicines with multi-target action to combat the diverse and treatment-resistant characteristics of CCA. Methods: An integrative computational strategy combining drug-likeness evaluation, target prediction, network pharmacology, Gene Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) enrichment analyses, and molecular docking was employed to elucidate the pharmacological profile of medicarpin, a natural pterocarpan derived from Dalbergia species. Overlapping targets between medicarpin and CCA-related genes were analysed to construct a protein–protein interaction (PPI) network and identify hub genes. Results: Forty-four overlapping targets were identified, with mTOR, SRC, PIK3CA, and CCND1 emerging as central nodes within the network. Enrichment analyses revealed significant involvement in carcinogenic pathways, including PI3K–Akt/mTOR, ErbB signalling, apoptosis regulation, and drug resistance. Molecular docking demonstrated a stable binding of medicarpin within the catalytic pocket of mTOR (binding energy −9.6 kcal/mol), supported by multiple hydrogen bonds and hydrophobic interactions with key residues essential for kinase activation. Conclusions: This study provides systems-level evidence that medicarpin exerts polypharmacological activity against CCA, with mTOR indicated as a possible mechanistic hub. These findings highlight medicarpin’s potential as a promising multi-target therapeutic candidate and underscore the value of natural compounds in expanding treatment strategies for cholangiocarcinoma.
Open AccessComputational Investigation Identifies mTOR as a Primary Binding Target of Medicarpin in Cholangiocarcinoma: Insights from Network Pharmacology and Molecular Docking
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of biliary tract with poor prognosis and limited therapeutic alternatives. While targeted medicines only benefit a small subset of patients with specific genetic modifications, conventional chemotherapy offers negligible survival advantages. There is an urgent need for novel medicines with multi-target action to combat the diverse and treatment-resistant characteristics of CCA. Methods: An integrative computational strategy combining drug-likeness evaluation, target prediction, network pharmacology, Gene Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) enrichment analyses, and molecular docking was employed to elucidate the pharmacological profile of medicarpin, a natural pterocarpan derived from Dalbergia species. Overlapping targets between medicarpin and CCA-related genes were analysed to construct a protein–protein interaction (PPI) network and identify hub genes. Results: Forty-four overlapping targets were identified, with mTOR, SRC, PIK3CA, and CCND1 emerging as central nodes within the network. Enrichment analyses revealed significant involvement in carcinogenic pathways, including PI3K–Akt/mTOR, ErbB signalling, apoptosis regulation, and drug resistance. Molecular docking demonstrated a stable binding of medicarpin within the catalytic pocket of mTOR (binding energy −9.6 kcal/mol), supported by multiple hydrogen bonds and hydrophobic interactions with key residues essential for kinase activation. Conclusions: This study provides systems-level evidence that medicarpin exerts polypharmacological activity against CCA, with mTOR indicated as a possible mechanistic hub. These findings highlight medicarpin’s potential as a promising multi-target therapeutic candidate and underscore the value of natural compounds in expanding treatment strategies for cholangiocarcinoma.
- 3 June 2025
- Published by Springer Nature in Human Cell
- Vol. 38 (4) , 1-14
Establishment and characterization of TK-DDCS1: a novel IDH1 mutated dedifferentiated chondrosarcoma cell line
Dedifferentiated chondrosarcoma (DDCS) is a rare and aggressive subtype of chondrosarcoma, characterized by the coexistence of a high-grade spindle or pleomorphic tumor that lacks a substantial cartilaginous matrix. Notably, it shows a mutant IDH1 incidence of over 80%. This study established a novel DDCS cell line with an IDH1 mutation, TK-DDCS1, derived from the right ilium of a 67-year-old Japanese female patient. TK-DDCS1 cells maintain the undifferentiated DDCS phenotype with the IDH1p.R132L mutation. The IDH1R132 mutation is known to be associated with a poor prognosis for chondrosarcoma, and the p.R132L mutation is a novel variant among the registered DDCS cell lines in the Cellosaurus database. The mutant IDH1 inhibitor, DS-1001b, inhibited the proliferation of TK-DDCS1 in a dose-dependent manner in both two-dimensional and spheroid cultures. The tumorigenicity of TK-DDCS1 was demonstrated through xenografting into EGFP-transgenic BALB/c Rag2-/-/Jak3-/- (EGFP-BRJ) mice, where the tumors exhibited undifferentiated phenotypes of DDCS in both morphological and immunohistochemical features. Thus, TK-DDCS1 serves as a valuable model for investigating the characteristics of DDCS and exploring molecular targeted therapies.
- 3 June 2025
- Published by Springer Nature in Human Cell
- Vol. 38 (4) , 1-14
Establishment and characterization of TK-DDCS1: a novel IDH1 mutated dedifferentiated chondrosarcoma cell line
Dedifferentiated chondrosarcoma (DDCS) is a rare and aggressive subtype of chondrosarcoma, characterized by the coexistence of a high-grade spindle or pleomorphic tumor that lacks a substantial cartilaginous matrix. Notably, it shows a mutant IDH1 incidence of over 80%. This study established a novel DDCS cell line with an IDH1 mutation, TK-DDCS1, derived from the right ilium of a 67-year-old Japanese female patient. TK-DDCS1 cells maintain the undifferentiated DDCS phenotype with the IDH1p.R132L mutation. The IDH1R132 mutation is known to be associated with a poor prognosis for chondrosarcoma, and the p.R132L mutation is a novel variant among the registered DDCS cell lines in the Cellosaurus database. The mutant IDH1 inhibitor, DS-1001b, inhibited the proliferation of TK-DDCS1 in a dose-dependent manner in both two-dimensional and spheroid cultures. The tumorigenicity of TK-DDCS1 was demonstrated through xenografting into EGFP-transgenic BALB/c Rag2-/-/Jak3-/- (EGFP-BRJ) mice, where the tumors exhibited undifferentiated phenotypes of DDCS in both morphological and immunohistochemical features. Thus, TK-DDCS1 serves as a valuable model for investigating the characteristics of DDCS and exploring molecular targeted therapies.